Obesity Treatment
60 articles on Obesity Treatment, researched and written by the Shotlee Editorial Team from primary sources.
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.
8 min read
Semaglutide for Weight Loss in Adults Over 65: New Study Findings
A recent analysis of the STEP trials reveals that semaglutide, the active ingredient in popular medications like Ozempic and Wegovy, offers significant weight loss and health benefits for adults over 65 with obesity, with a safety profile comparable to younger populations.
8 min read
I Lost 5 Stone on Mounjaro — But Now I’ve Had Enough
Natalie Lavergne transformed her health and lost 5 stone using Mounjaro, but now plans to switch to the Wegovy pill. Discover the medical realities of stopping weight loss medication.
8 min read
New “Trojan Horse” Drug Supercharges Weight Loss in Early Trials
A new hybrid molecule designed by Helmholtz Munich researchers acts as a Trojan horse to deliver metabolic compounds directly into cells, showing superior weight loss in mice compared to standard treatments.
8 min read
Eli Lilly Prepares FDA Run for ‘Triple-G’ Weight Loss Drug With Phase 3 Data
Eli Lilly has announced positive Phase 3 results for retatrutide, positioning the triple-agonist drug for an FDA filing in 2027 with substantial weight loss outcomes.
7 min read
Novo Nordisk Sues Eli Lilly Over Which GLP-1 Sheds the Most Pounds
Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising regarding the comparative weight loss efficacy of Zepbound and Wegovy. The dispute centers on dosage comparisons and clinical trial data interpretation.
8 min read
Eli Lilly to Seek FDA Approval for Obesity Drug Retatrutide
Eli Lilly announces plans to file for FDA approval of its triple-agonist obesity drug retatrutide in early 2027 following successful Phase 3 trial data.
8 min read
AI Helps Stanford Scientists Discover Natural Ozempic Without the Usual Side Effects
Stanford Medicine researchers have identified a naturally occurring molecule that may suppress appetite and reduce body weight in a way that resembles semaglutide, the active ingredient in Ozempic.
8 min read
Novo Nordisk Sues Eli Lilly, Alleging Misleading Advertising of Obesity Drugs
Novo Nordisk has filed a lawsuit against Eli Lilly in New Jersey, claiming deceptive advertising regarding GLP-1 and dual-agonist weight loss medications.
7 min read
Study Links GLP-1 Medications To Rare Vision Issue
New research indicates a possible association between GLP-1 medications, commonly prescribed for type 2 diabetes and weight management, and a rare but serious vision issue. This article explores the study's findings, potential implications, and expert recommendations.
6 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell shares her candid experience with Mounjaro, detailing her 30kg weight loss, Type 2 diabetes management, and the physical consequences of rapid fat loss.
12 min read
Ozempic Maker Novo Nordisk Sues Eli Lilly Over 'Materially Misleading' Ads
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging deceptive advertising regarding weight-loss drugs. This legal battle highlights the intense competition between semaglutide and tirzepatide.
9 min read
GLP-1s for Teen Weight Loss: A New Treatment Trend?
GLP-1 medications are rapidly changing obesity care for teens and young adults, with a notable shift away from bariatric surgery. This article delves into the latest research, potential benefits, and important considerations for this emerging trend.
7 min read
Medicare's New GLP-1 Weight-Loss Drug Program: What to Know
Medicare is launching a new pilot program to increase access to GLP-1 medications for weight loss, offering a $50 monthly copay for eligible beneficiaries. This marks a significant step in covering obesity as a medical condition.
9 min read
People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less
New data presented at ENDO 2026 reveals a paradox: patients on GLP-1 medications like Ozempic and Wegovy reduced their physical activity despite losing weight.
8 min read
Ozempic and Wegovy Use Linked to Thousands of Poison Control Calls
The widespread adoption of Ozempic and Wegovy for weight loss has coincided with a significant rise in calls to poison control centers. This article delves into the research behind this trend, highlighting common mistakes and the importance of proper patient education.
6 min read
Ozempic, Wegovy, and Mounjaro May Alter Taste: How Food Flavor Changes Can Impact Cravings
Discover how incretin-based therapies like Ozempic, Wegovy, and Mounjaro might be changing the way you experience food. This article delves into new research linking altered taste perception to reduced appetite and cravings, offering insights for patients and clinicians.
8 min read
The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss
While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.
6 min read
GLP-1 Medications for Obesity: Experts See a Broader Revolution Ahead
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
6 min read
Ozempic's Oral Twin: A Needle-Free Weight Loss Revolution Arrives?
A new era in weight management may be dawning as an oral medication, mirroring the efficacy of popular injectables like Ozempic, is poised for approval. This development promises a more accessible and convenient path to weight loss for millions.
7 min read
Ozempic Generics Recall: Why Cheap Semaglutide Copies Are Being Pulled
India's booming generic semaglutide market faces a credibility crisis as major manufacturers recall batches over quality concerns. Discover the implications for patient safety and treatment continuity.
9 min read
Semaglutide Supply Chain Halted: What Dr. Reddy's API Issue Means for You
Dr. Reddy's Laboratories has paused semaglutide shipments due to active ingredient quality concerns. Here is a deep dive into the impact on the GLP-1 market and patient care.
7 min read
Beyond the Hype: Understanding GLP-1s and Weight Management
The rise of GLP-1 medications has revolutionized weight management. This comprehensive guide delves into semaglutide, tirzepatide, and other peptide therapies, offering insights into their efficacy, potential side effects, and how to track your progress effectively.
7 min read
GLP-1 Regain Risk: Why Weight Loss Benefits Fade Fast After Stopping
A significant new meta-analysis highlights a critical challenge for individuals using GLP-1 medications like Semaglutide and Tirzepatide: rapid weight regain upon cessation. Researchers suggest obesity requires chronic management, similar to other long-term conditions.
6 min read
Ozempic & Wegovy for Kids? Doctor Warns of Dangers
While GLP-1 medications show promise for adult obesity, their use in children is raising significant concerns. A medical expert weighs in on the potential dangers and the critical need for specialist oversight.
7 min read
Svemia Approved: What Canada's New Semaglutide Generic Means for You
Canada's Health Department has cleared Apotex's Svemia, marking a major milestone for generic semaglutide availability and weight loss treatment access.
7 min read
Navigating Medicare's New Path for GLP-1 Weight Loss Coverage
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
6 min read
Ozempic, Wegovy, Mounjaro: How Do They Affect Mental Health?
New research sheds light on the neuropsychiatric effects of popular weight loss medications like semaglutide and tirzepatide. Discover how these treatments may influence anxiety, depression, and other mental health outcomes.
7 min read
Medicare's GLP-1 Weight Loss Drug Bridge: What You Need to Know
For the first time, Medicare is expanding access to GLP-1 medications for weight loss through a new pilot program. Starting July 1, eligible beneficiaries can access popular drugs like Wegovy and Zepbound for a $50 monthly copay. This groundbreaking initiative aims to make these life-changing treatments more accessible, but understanding the specifics is crucial.
7 min read
Tirzepatide vs. Semaglutide: Which Weight Loss Peptide Reigns Supreme?
The landscape of medical weight loss has been revolutionized by potent peptide therapies. Among the most talked-about are semaglutide and tirzepatide, the active ingredients in popular medications like Wegovy, Ozempic, Zepbound, and Mounjaro. But when it comes to shedding pounds, which one truly takes the lead? This article delves into the science, the studies, and the practical differences to help you understand their comparative effectiveness.
7 min read
Mounjaro Access Expands: Northern Ireland Launches New Weight Loss Service
Northern Ireland is set to launch a £5 million Regional Obesity Management Service, improving access to Mounjaro and lifestyle support for adults struggling with obesity.
8 min read
Ozempic, Wegovy, Mounjaro: Navigating the New GLP-1 Landscape
The landscape of GLP-1 medications for weight loss and chronic disease management is rapidly evolving. From new access programs to shifting pricing dynamics, understanding these advancements is crucial for patients and healthcare providers alike.
6 min read
Oral Wegovy in the UK: A New Era for Weight Management
Novo Nordisk's groundbreaking approval of an oral GLP-1 for weight management in the UK marks a significant shift, promising wider accessibility and influencing consumer markets.
6 min read
Beyond the Hype: Navigating GLP-1s for Sustainable Health
As demand for GLP-1 medications soars, healthcare professionals emphasize a balanced, comprehensive approach to weight management and chronic disease treatment, focusing on sustainability and patient well-being.
7 min read
Zepbound vs. Wegovy: New Meta-Analysis Reveals Top Weight Loss Drug
A comprehensive meta-analysis from the University of Georgia has finally put major weight loss medications head-to-head. Here is what the data says about Zepbound, Wegovy, and Saxenda.
8 min read
Ozempic Alternative Found: Stanford’s BRP Peptide Breakthrough
A new study reveals BRP, a natural peptide, may offer the benefits of Ozempic without common side effects.
7 min read
Beyond Ozempic: Why Zepbound Might Be the Heavyweight Champion for Weight Loss
A comprehensive review of the latest clinical data comparing Tirzepatide, Semaglutide, and Liraglutide to determine the most effective option for significant weight reduction.
8 min read
GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight
The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.
6 min read
Wegovy Pill Arrives in the UK: A New Era for Weight Management?
The UK has officially approved a pill version of the popular Wegovy weight-loss drug, marking a significant advancement in accessible obesity treatment. This development offers a convenient alternative to weekly injections for many.
6 min read
Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds
A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.
7 min read
Ozempic, Wegovy, Mounjaro: Why Rhode Island Medicaid Must Cover Obesity Meds
Rhode Island's strategic health initiatives are commendable, but a recent budget proposal to cut Medicaid coverage for GLP-1 obesity treatments like Ozempic and Wegovy raises serious concerns. This decision, while seemingly a cost-saving measure, risks long-term health consequences and increased healthcare expenditures.
6 min read
Oral Wegovy's Record-Breaking Launch: The New Era of Needle-Free Weight Loss
Novo Nordisk's Wegovy oral formulation has achieved unprecedented prescription rates, marking a pivotal shift in obesity care and intensifying competition with Eli Lilly.
8 min read
Wegovy Pill Launch: Why 80% of Patients Are Choosing Oral Semaglutide
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
9 min read
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
7 min read
Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?
Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.
7 min read
Beyond Ozempic: New Muscle-Burning Pill Reshaping Diabetes Care
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
6 min read
Wegovy and Zepbound on Medicare: What the $50 Co-Pay Means for Your Health
A new federal agreement could lower the cost of popular weight-loss medications like Wegovy and Zepbound to $50 per month for eligible Medicare beneficiaries. Here is what you need to know about eligibility and clinical impact.
7 min read
Wegovy Pill Arrives: A New Era for Oral Weight Management in the UAE
Novo Nordisk's revolutionary Wegovy pill (oral semaglutide) is set to transform weight management in the UAE. Discover the details of its early access launch, clinical benefits, and how it integrates into advanced care pathways.
7 min read
Ozempic & Beyond: Are GLP-1s Shifting America's Obesity Battle?
Once a distant rumor, the idea of widespread obesity in America is now being challenged by a new wave of medications. Discover how GLP-1 drugs are changing the landscape of weight management and what it means for public health.
8 min read
GLP-1 Therapies: Australia's New Blueprint for Obesity and Heart Health
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
6 min read
Ozempic, Wegovy: New Insights Into Brain Receptors Could Revolutionize Dosing
Millions are experiencing transformative weight loss with GLP-1 agonists like Ozempic and Wegovy. However, many encounter plateaus. Groundbreaking research from the NIH is shedding light on why this happens within the brain's appetite control centers, potentially paving the way for more effective and personalized treatment plans.
6 min read
Beyond the Injection: GLP-1s, Diet, and the Future of Weight Management
GLP-1 receptor agonists have revolutionized obesity and diabetes management, offering unprecedented appetite control. However, as adoption surges, especially in markets like India, medical experts emphasize that these powerful tools must be integrated with fundamental lifestyle changes and supportive public health infrastructure to ensure lasting success.
6 min read
Retatrutide: The Next Frontier in Weight Loss and Its Profound Implications
Eli Lilly's experimental drug retatrutide is showing unprecedented weight loss results, pushing the boundaries of what's possible. But with great power comes great responsibility, and doctors are urging caution.
7 min read
Retatrutide's Rapid Weight Loss: Balancing Benefits and Risks
New-generation GLP-1 drugs like retatrutide promise unprecedented weight loss, but what are the implications for your body's composition and overall health? This article delves into the science, risks, and strategies for navigating rapid weight reduction.
8 min read
Semaglutide Plateaus: New Brain Discovery Could Boost Weight Loss Results
New research from the NIH reveals how semaglutide signaling in the brain affects weight loss plateaus, offering hope for improved efficacy and dosing strategies.
7 min read
Oral GLP-1s Enter the Ring: Early Trends Favoring Foundao Over Wegovy's Pill
The landscape of weight loss treatments is rapidly changing with the introduction of oral GLP-1 medications. This article delves into early adoption trends, comparing the initial uptake of Eli Lilly's oral semaglutide (Foundao) against Novo Nordisk's oral semaglutide (Wegovy's pill), and what these patterns signify for patients and physicians.
6 min read
Wegovy & Mounjaro Boom Fuels Peptide Production Surge for GLP-1 Drugs
The unprecedented demand for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is triggering a significant global expansion in peptide manufacturing. Learn how key players are investing billions to meet the surging need for these life-changing therapies.
7 min read
Beyond BMI: Why Mounjaro Eligibility is More Complex Than You Think
Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.
6 min read
Mounjaro vs. Wegovy: Decoding the Global Shift in Weight Loss Therapy
The competition between Eli Lilly and Novo Nordisk is reshaping obesity treatment. Learn the clinical differences between Mounjaro and Wegovy, and why international market dynamics matter for patient access.
7 min read